Utility Menu French

National Association of Pharmacy Regulatory Authorities

Provinces French

Main navigation French


Recherchez dans la base de données des Annexes nationales de médicaments

Commencez votre recherche en utilisant le nom générique du produit :

Recherche par annexe
Réinitialiser

ATTENTION : Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais.

Nom du médicament (en anglais) Commentaire Annexe Date
Dioxaphetyl butyrateN I JUN / 02
Diperodon and its salts except for topical use II SEP / 98
Diphenhydramine and its salts and preparations for parenteral use II SEP / 98
Diphenhydramine and its salts and preparations. except for parenteral or topical use III SEP / 98
Diphenhydramine and its salts and preparations.. for topical use in concentrations of greater than 2% II MAY / 06
Diphenhydramine and its salts and preparations... for topical use in concentrations of 2% or less when sold in containers of greater than 300 mg of diphenhydramine hydrochloride III MAY / 06
Diphenhydramine and its salts and preparations... for topical use in concentrations of 2% or less when sold in containers of 300 mg or less of diphenhydramine hydrochloride U OCT / 09
Diphenidol or its saltsPDL I DEC / 13
DiphenoxylateN I JUN / 02
Diphenylhydantoin (phenytoin) or its saltsPDL I SEP / 98
Diphenylmorpholinoisovaleric acidN I JUN / 02
Diphenylpyraline III SEP / 98
Diphtheria toxoid II DEC / 98
DipipanoneN I JUN / 02
Dipivefrin or its saltsPDL I DEC / 13
Diprophylline or its saltsPDL I DEC / 13
DipyridamolePDL I DEC / 13
DirithromycinPDL

For human use

I DEC / 13
DirlotapidePDL I DEC / 13
Disopyramide or its saltsPDL I DEC / 13
DisulfiramPDL I DEC / 13
Dithranol Anthralin II SEP / 98
Dobutamine or its saltsPDL I DEC / 13
Docetaxel or its derivativesPDL

including but not limited to cabazitaxel

I DEC / 13
Docusate and its salts U
Dolasetron or its saltsPDL I DEC / 13
Dolutegravir or its saltsPDL I DEC / 13
DomperidonePDL I DEC / 13
Donepezil or its saltsPDL I DEC / 13
Dopamine or its saltsPDL

when sold for administration by injection

I DEC / 13
DoravirinePDL I NOV / 18
Dornase alfaPDL I DEC / 13
Dorzolamide or its saltsPDL I DEC / 13
Doxacurium chloridePDL I DEC / 13
DoxapramPDL I DEC / 13
Doxazosin or its saltsPDL I DEC / 13
Doxepin or its saltsPDL I DEC / 13
Doxercalciferol or its derivativesPDL I DEC / 13
Doxorubicin or its saltsPDL I DEC / 13
Doxycycline or its salts or derivativesPDL

including but not limited to doxycycline hyclate, doxycycline monohydrate

I DEC / 13
Doxylamine or its salts

except those sold for nausea and vomiting of pregnancy

III SEP / 98
Doxylamine or its saltsPDL

when sold or recommended for use in the nausea or vomiting of pregnancy

I DEC / 13
Droperidol or its saltsPDL I DEC / 13
DrostanoloneC3 I JUN / 02
DrotebanolN I JUN / 02
DrotrecoginPDL I DEC / 13
DulaglutidePDL I JAN / 16
Duloxetine or its saltsPDL I DEC / 13
DupilumabPDL I MAR / 18
DurvalumabPDL I DEC / 17
DutasteridePDL I DEC / 13
Dyclonine except for topical use on mucous membranes II SEP / 98
Dyclonine and its salts for topical use on mucous membranes, except lozenges III SEP / 98

153 résultats


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled